Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs

Alector Files for IPO to Fund Studies of Alzheimer’s, Dementia Drugs

Source: 
Xconomy
snippet: 

Alector, a biotech company focusing on the immune system to treat degenerative brain disorders such as Alzheimer’s disease, has filed to go public to fund human tests of its experimental therapies.